Clear Street adjusted the firm’s price target on Rapt Therapeutics (RAPT) to $24 from $3 and keeps a Buy rating on the shares following the 1:8 reverse stock split.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- Rapt Therapeutics upgraded to Neutral from Underweight at JPMorgan
- LifeSci starts Rapt Therapeutics at Outperform on potential for lead asset
- Rapt Therapeutics initiated with an Outperform at LifeSci Capital
- RAPT Therapeutics: Promising Growth Potential with Innovative Immunology Developments
- RAPT Therapeutics trading resumes